Insider Selling: Tabula Rasa HealthCare Inc (TRHC) Director Sells $387,750.00 in Stock
Tabula Rasa HealthCare Inc (NASDAQ:TRHC) Director Gordon Tunstall sold 15,000 shares of the firm’s stock in a transaction that occurred on Friday, December 8th. The shares were sold at an average price of $25.85, for a total value of $387,750.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
Tabula Rasa HealthCare Inc (NASDAQ:TRHC) opened at $27.76 on Thursday. The company has a quick ratio of 0.66, a current ratio of 0.73 and a debt-to-equity ratio of 0.47. Tabula Rasa HealthCare Inc has a 1 year low of $11.59 and a 1 year high of $36.80.
Tabula Rasa HealthCare (NASDAQ:TRHC) last released its quarterly earnings results on Monday, November 6th. The company reported $0.08 earnings per share for the quarter, topping the consensus estimate of $0.06 by $0.02. The company had revenue of $33.27 million during the quarter, compared to the consensus estimate of $31.76 million. Tabula Rasa HealthCare had a negative return on equity of 5.58% and a negative net margin of 2.27%. Tabula Rasa HealthCare’s revenue was up 37.6% compared to the same quarter last year. During the same quarter last year, the business posted $0.06 earnings per share. analysts predict that Tabula Rasa HealthCare Inc will post 0.05 earnings per share for the current fiscal year.
Several research firms recently weighed in on TRHC. Zacks Investment Research downgraded Tabula Rasa HealthCare from a “strong-buy” rating to a “hold” rating in a research note on Friday, November 10th. BidaskClub downgraded Tabula Rasa HealthCare from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, December 6th. First Analysis began coverage on Tabula Rasa HealthCare in a research note on Wednesday, November 1st. They issued an “overweight” rating and a $41.00 price objective for the company. William Blair began coverage on Tabula Rasa HealthCare in a research note on Monday. They issued an “outperform” rating for the company. Finally, Piper Jaffray Companies reaffirmed an “overweight” rating and issued a $35.00 price objective on shares of Tabula Rasa HealthCare in a research note on Tuesday, November 7th. They noted that the move was a valuation call. Three analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus target price of $28.25.
A number of institutional investors have recently added to or reduced their stakes in TRHC. TIAA CREF Investment Management LLC increased its position in Tabula Rasa HealthCare by 108.5% during the first quarter. TIAA CREF Investment Management LLC now owns 8,131 shares of the company’s stock worth $110,000 after buying an additional 4,232 shares in the last quarter. New York State Common Retirement Fund increased its position in Tabula Rasa HealthCare by 257.0% during the second quarter. New York State Common Retirement Fund now owns 10,000 shares of the company’s stock worth $151,000 after buying an additional 7,199 shares in the last quarter. Cadence Capital Management LLC purchased a new position in Tabula Rasa HealthCare during the second quarter worth $210,000. Financial Consulate Inc. purchased a new position in Tabula Rasa HealthCare during the third quarter worth $222,000. Finally, Teachers Advisors LLC increased its position in Tabula Rasa HealthCare by 203.5% during the second quarter. Teachers Advisors LLC now owns 16,500 shares of the company’s stock worth $248,000 after buying an additional 11,063 shares in the last quarter. 31.85% of the stock is owned by institutional investors.
About Tabula Rasa HealthCare
Tabula Rasa HealthCare, Inc (Tabula Rasa), formerly CareKinesis, Inc, is a provider of patient-specific, data-driven technology and solutions that enable healthcare organizations to optimize medication regimens to improve patient outcomes, reduce hospitalizations and manage risk. The Company delivers its solutions through a suite of technology-enabled products and services for medication risk management, which includes bundled prescription fulfillment and adherence packaging services for client populations with complex prescription needs.
Receive News & Ratings for Tabula Rasa HealthCare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tabula Rasa HealthCare and related companies with MarketBeat.com's FREE daily email newsletter.